×
About 10,555 results

ALLMedicine™ Cholangiocarcinoma Center

Research & Reviews  3,880 results

Prognostic factors of recurrent intrahepatic cholangiocarcinoma after hepatectomy: A re...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048463
World Journal of Gastroenterology; Yuan ZB, Fang HB et. al.

May 19th, 2022 - Intrahepatic cholangiocarcinoma (ICC) is a highly malignant tumour. Hepatectomy is an effective treatment for early ICC, but postoperative recurrence greatly affects patient survival. Studies on recurrent ICC after hepatectomy are lacking. To inve...

Novel approaches in search for biomarkers of cholangiocarcinoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048460
World Journal of Gastroenterology; Mocan LP, Ilieș M et. al.

May 19th, 2022 - Cholangiocarcinoma (CCA) arises from the ductular epithelium of the biliary tree, either within the liver (intrahepatic CCA) or more commonly from the extrahepatic bile ducts (extrahepatic CCA). This disease has a poor prognosis and a growing worl...

Lymphadenectomy and margin-negative resection for biliary tract cancer surgery in the U...
https://doi.org/10.1002/jso.26924
Journal of Surgical Oncology; Kim BJ, Newhook TE et. al.

May 18th, 2022 - As minimally invasive surgery (MIS) approaches to biliary tract cancers become more commonplace, understanding the adequacy of their oncologic performance is key. The National Cancer Database 2010-2016 was queried for patients who underwent hepate...

Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future di...
https://doi.org/10.1136/gutjnl-2022-327099
Gut Macias RIR, Cardinale V et. al.

May 18th, 2022 - Cholangiocarcinoma (CCA) is a malignant tumour arising from the biliary system. In Europe, this tumour frequently presents as a sporadic cancer in patients without defined risk factors and is usually diagnosed at advanced stages with a consequent ...

NOTCH-YAP1/TEAD-DNMT1 axis drives hepatocyte reprogramming into intrahepatic cholangioc...
https://doi.org/10.1053/j.gastro.2022.05.007
Gastroenterology Hu S, Molina L et. al.

May 14th, 2022 - Intrahepatic cholangiocarcinoma (ICC) is a devastating liver cancer with extremely high intra- and inter-tumoral molecular heterogeneity, partly due to its diverse cellular origins. We investigated clinical relevance and the molecular mechanisms u...

see more →

Guidelines  9 results

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice G...
https://doi.org/10.1016/j.prro.2021.09.004
Practical Radiation Oncology; Apisarnthanarax S, Barry A et. al.

Oct 25th, 2021 - This guideline provides evidence-based recommendations for the indications and technique-dose of external beam radiation therapy (EBRT) in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC). The American Society for Radiation...

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0022
Journal of the National Comprehensive Cancer Network : JN... Benson AB, D'Angelica MI et. al.

May 25th, 2021 - The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcino...

Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd ...
https://doi.org/10.1002/jhbp.870
Journal of Hepato-biliary-pancreatic Sciences; Nagino M, Hirano S et. al.

Dec 2nd, 2020 - The Japanese Society of Hepato-Biliary-Pancreatic Surgery launched the clinical practice guidelines for the management of biliary tract cancers (cholangiocarcinoma, gallbladder cancer, and ampullary cancer) in 2007, then published the 2nd version ...

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With...
https://doi.org/10.1016/j.cgh.2019.07.011
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.

Jul 16th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Clinical practice guidelines for IgG4-related sclerosing cholangitis.
https://doi.org/10.1002/jhbp.596
Journal of Hepato-biliary-pancreatic Sciences; Kamisawa T, Nakazawa T et. al.

Dec 24th, 2018 - IgG4-related sclerosing cholangitis (IgG4-SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4-related disease. Although clinical diagnostic criteria o...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  144 results

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
https://clinicaltrials.gov/ct2/show/NCT04566133

May 13th, 2022 - Background: Among the new cases of bile tract carcinoma (BTC) that are diagnosed every year in the United States, there are approximately 6,500 cases of gallbladder carcinoma, 3,000 cases of extrahepatic cholangiocarcinoma, and 3,000 cases of intr...

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
https://clinicaltrials.gov/ct2/show/NCT04521686

Apr 28th, 2022 - This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with IDH1 R132-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, ...

Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT02773485

Apr 27th, 2022 - Currently the standard of care of unresectable non-metastatic cholangiocarcinoma is chemotherapy which has a median survival of 11.7 months (ABC-02 study). While this study included almost 60% of patients with cholangiocarcinomas (intrahepatic, ex...

Clinical Trial of Autologous Tcm Immunotherapy in ICC
https://clinicaltrials.gov/ct2/show/NCT03820310

Apr 26th, 2022 - Intrahepatic cholangiocarcinoma (ICC) accounts for 2%~3% of gastrointestinal tumors, and the incidence has been on the rise globally. The pathogenesis of ICC remains unclearly. Compared with palliative resection, the postoperative survival rate of...

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT04088188

Apr 25th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose, gemcitabine and cisplatin in combination with either ivosidenib or pemigatinib. SECONDARY OBJECTIVES: I. To evaluate median a...

see more →

News  179 results

What Is the Optimal Treatment for Multifocal Intrahepatic Cholangiocarcinoma?
https://www.medscape.com/viewarticle/974146

May 18th, 2022 - NEW YORK (Reuters Health) - In patients with multifocal intrahepatic cholangiocarcinoma (iCCA), hepatic arterial infusion pump (HAIP) floxuridine chemotherapy may be an effective alternative to surgery, a cohort study suggests. "We believe that th...

European Approval Sought for Ivosidenib in IDH1-Mutated AML and Cholangiocarcinoma
https://www.onclive.com/view/european-approval-sought-for-ivosidenib-in-idh1-mutated-aml-and-cholangiocarcinoma

Apr 22nd, 2022 - A marketing authorization application (MAA) has been submitted to the European Medicines Agency (EMA) for 2 indications of ivosidenib (Tibsovo): in combination with azacitidine in the frontline treatment of patients with IDH1-mutated acute myeloid...

KIN-3248 Under Exploration in Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Alterations
https://www.onclive.com/view/kin-3248-under-exploration-in-advanced-solid-tumors-harboring-fgfr2-and-or-fgfr3-alterations

Apr 21st, 2022 - The safety, tolerability, and preliminary efficacy of the irreversible, small molecule pan-FGFR inhibitor KIN-3248 is under investigation in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations, as part of the phase 1 ...

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

see more →

Patient Education  7 results see all →